Home
Back to work
Symphony Neuro Inc.

The clinical platform that makes deep-brain neuromodulation non-invasive and scalable.

The Revolution in Brain Stimulation Made Possible with Low Intensity Focused Ultrasound
One device, any target. Electronic steering places the focus on any brain region — or several at once — in whatever spatial pattern an indication demands.
Symphony Neuro Inc. is building Maestro© — a software-first platform for low-intensity focused ultrasound (LIFU) that targets any brain region with millimetre precision, requires no surgery, and can be run by a technician.

Investor materials & inquiries

Review the deck, one-pager, and executive summary — or reach out to discuss the opportunity.

Email
First page preview of Executive Summary
01
PDF
Executive summary
First page preview of Primer 1 — LIFU Technical Overview
02
PDF
LIFU technical overview
First page preview of Primer 2 — LIFU Mechanisms
03
PDF
LIFU mechanisms
First page preview of Primer 3 — Business & Revenue Model
04
PDF
Business & revenue model

Online Public Deck

Contents

Investment Thesis

01 / 08

The Right Software & Strategy can turn the nascent brain stimulation technique called "LIFU" into a readily-scalable platform for generic Brain Stimulation.

LIFU: Low Intensity Focused Ultrasound Offers Safe & Non-Invasive, Brain-Wide yet Millimeter-Precise, Neuromodulation for wide-ranging clinical adoption in Neurology and Psychiatry! Ultrasound hardware is commoditising. Symphony builds the software and protocols that make it clinically usable — and captures the margin.

The gap in neuromodulation today

Deep-brain neuromodulation works — but the tools that reach deep circuits require surgery, and the tools that avoid surgery cannot reach depth. The field has been stuck between efficacy and accessibility.

How Symphony closes it

Maestro© converts commodity ultrasound hardware into a standardised, MRI-optional, technician-run clinical system. The result is a durable software margin layered on inexpensive hardware, in a market measured in tens of millions of under-served patients.

Core platform advantage

  • Non-invasive targeting of deep-brain regions
  • Software-defined precision and treatment planning
  • Technician-run workflow, MRI-optional
  • Recurring SaaS revenue on commodity hardware
0.01 cm
LIFU focal precision — vs ~4 cm for TMS
>$260B
US TAM across the top seven CNS disorders
$3.3B
Beachhead SAM — medication-resistant Parkinson’s
<2%
Of eligible Parkinson’s patients ever receive DBS

Brand identity

Symphony Neuro wordmark with a spectral waveform swoosh
Symphony Neurotech circular logo mark